

Identification of genetic variants and their causal association underlying autism spectrum disorder

Prashasti Yadav¹, Mona Srivastava², Parimal Das¹

1. Centre for Genetic Disorders, Institute of Science, Banaras Hindu University, Varanasi-221005, Uttar Pradesh, India

2. Department of Psychiatry, Institute of Medical Sciences, Banaras Hindu University, Varanasi-221005, Uttar Pradesh, India

Abstract

Background: Autism spectrum disorder (ASD) is an early-onset neurodevelopmental disorder with a complex genetic architecture characterized by persistent deficits in social communication and social interaction along with restricted and repetitive behavior patterns, interests and activities. Over the years its prevalence has increased and affects 1% children globally. Etiology of ASD is remained unclear, but it is well recognized as a complex disorder involving interactions of several genes and environmental risk factors. Studies signify the role of whole exome sequencing in identifying rare genetic variation related to neurodevelopmental disorders and have greatly improved the chance of identifying known as well as novel responsible genes. This study aimed to identify genetic variant in a patient affected with autism spectrum disorder.

Methods: A male patient of age range 0-5 years was investigated and identified according to DSM-5 criteria for autism spectrum disorder. Peripheral blood sample was collected followed by genomic DNA extraction and whole exome sequencing. The functional impact of variant, gene interaction network and pathway enrichment analysis were done using *in silico* tools and databases.

Results: Two heterozygous missense variants one in *SHANK2* (c.401C>G) another in *CSNK2A1* (c.572G>A) were identified. Both of these variants were predicted to be deleterious by pathogenicity prediction tool. Gene interaction network and pathway enrichment analysis revealed the involvement of *SHANK2* and *CSNK2A1* in various biological pathways such as protein binding, synaptogenesis, chromosome condensation and cell cycle regulation.

Conclusion: This study revealed a novel *SHANK2* variant along with a known *CSNK2A1* variant that expands the spectrum of genetic variants related to autism spectrum disorder and

further enhances the understanding of the molecular mechanism underlying *SHANK2* and *CSNK2A1* pathophysiology.

Keywords: Neurodevelopment; whole exome sequencing; missense variation; gene network; gene set enrichment analysis.

Introduction

Autism Spectrum Disorder (ASD) is a childhood neurodevelopment disorder characterized by persistence deficits in social communication and social interaction as well as restricted and repetitive patterns of behavior. It is often present with cognitive impairments, language development delay and a spectrum of comorbidities, including hyperactivity and anxiety disorder [1]. Over the past few years, its prevalence has increased and affects about one in 100 children globally [2]. It is more common in male children than female children [3]. Because of the absence of reliable biomarkers, diagnosis is most often based on behavioural assessment of the children and also the therapeutic options are predominantly restricted to behavioural interventions [4, 5]. Aetiology of ASD remains unclear but now it is well recognised as a complex disorder involving interactions of several genes and environmental risk factors [6,7,8]. Family and twin studies indicated the significant genetic basis susceptibility and heritability of ASD [9,10]. There is increasing evidence that the genes involved in pathogenesis of ASD converge to common biological pathways that include chromatin modifiers, translational regulators, synapse formation and cortical development [11].

Mutations in genes that encode synaptic cell adhesion molecules and scaffolding proteins, such as neuroligins (NLGN), neurexins (NRXN) and SHANK family protein, have been reported in patients with ASD [12]. These proteins play significance role in the synapse formation and stabilization [13]. *De novo* deleterious *SHANK2* and *SHANK3* variants have been identified in individuals with intellectual disability (ID), autism spectrum disorder (ASD), developmental delay, and attention deficit and hyperactivity disorder [14, 15,16].

CSNK2A1 is also categorized as autism risk gene that is reported in the SFARI gene database as high confidence autism risk gene [17]. Rare *de novo CSNK2A1* variants have been identified in ASD probands from simplex families from the Simons Simplex Collection [18, 19] and also reported in children with an intellectual disability and dysmorphic facial features syndrome [20].

In present study two missense variants one in *SHANK2* (c.401C>G) and another in *CSNK2A1* (c.572G>A) were identified in a proband from a single Indian family by whole exome sequencing. In addition, we further explored the functional impact of variants and pathways involved to understand the molecular mechanisms of *SHANK2* and *CSNK2A1*. The findings, provide valuable insights for pathogenicity of genetic variants and shed light on the underlying molecular process involved in ASD and also confirm the efficacy of whole exome sequencing in detecting genetic variants in neurodevelopmental disorders.

Material and Methods

Recruitment of patient and sample collection

Patient was enrolled from eastern Uttar Pradesh, India. The peripheral blood sample was collected after obtaining the written informed consent from parents, as the proband was minor. The study protocol was approved by the Institutional Ethics Committee of Centre for Genetic Disorders, Institute of Science, Banaras Hindu University, Varanasi.

The diagnosis of ASD was done according to the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria [1], and also evaluation was done using standard scale, IASQ (The Indian Autism Screening Questionnaire) [21].

DNA Extraction, whole exome sequencing and variant filtration

Genomic DNA was extracted using standard salting out method. Whole exome sequencing was performed using Illumina next-generation sequencing. Sequencing of approximately 30Mb of the human exome, targeting approximately 99% of regions in CCDS and RefSeq was performed. Complete mitochondrial genome sequencing was also performed at a mean depth of 80-100X. Percentage of bases covered was at 20X depth >90% in the target region and for the mitochondrial genome at 1000-2000X depth. Variant was identified using GATK best practice framework. Duplicate reads were identified and removed, base quality was recalibrated and re-alignment were done using DRAGEN BIO IT platform. Variant annotation was done using published databases like OMIM, GWAS, GNOMAD, 1000Genome and ClinVar.

***In silico* function prediction**

Pathogenicity and functional impact of variants were determined using *in silico* tool, Mutation Taster [22].

Interaction Network and Gene Set Enrichment Analysis

We used freely accessible and user-friendly web tools GeneMANIA (<http://www.genemania.org/>) and STRING (<https://string-db.org/>) for networks construction and analysis.

Gene Multiple Association Network Integration Algorithm (GeneMANIA) is a web-based tool for prediction of gene function based on single gene or gene set query [23, 24].

Search Tool for the Retrieval of Interacting Genes (STRING) is an online protein-protein interaction database curated from literature and predicted associations. [25].

Gene set enrichment analysis was done using Enrichr tool, it is a freely available comprehensive resource and a search engine for gene set [26].

Results

Clinical Description of Patient

This study includes a single Indian family. Proband is a male of 0-5 years age range, second child born out of non-consanguineous marriage. He has no family history of ASD or neurodevelopmental disorder. Clinical features include loss of eye contact, repetitive behaviour, delayed walking and facial dysmorphism. Brain MRI investigation was normal.

WES analysis

We identified two heterozygous missense variants one in *SHANK2* (c.401C>G) and another in *CSNK2A1* (c.572G>A). The pathogenicity of both variants was predicted as deleterious by *in silico* tool, Mutation Taster [Table1]

Table 1. Variants identified in *SHANK2* and *CSNK2A1* genes in proband in this study

Gene & transcript	Location	Nucleotide Substitution	Amino Acid Change	Zygosity	Mutation taster	ClinVar	Population Frequency (ExAC/gnomAD)
<i>SHANK2</i> NM_012309.	Exon 4	c.401C>G	p.Pro134Arg	Heterozygous	Disease causing	NA	0/0

5							
<i>CSNK2A1</i> NM_177559. 3	Exon 9	c.572G>A	Arg191Gln	Heterozygous	Disease causing	NA	0/0

NA: Not available

Interaction Network and Gene Set Enrichment Analysis

In order to understand the functional implication of *SHANK2* and *CSNK2A1* we performed gene interaction network and gene set enrichment analysis.

Gene network derived from GeneMANIA database using *SHANK2* and *CSNK2A1* as input genes, moreover another 20 strongly connected genes in network are, *CSNK2B*, *CSNK2A2*, *TOP2A*, *DVLI1*, *PINI1*, *APC*, *DNM2*, *SSTR2*, *STX4*, *ARHGEF7*, *NCAPD2*, *NCAPG*, *NCAPH*, *SUPT16H*, *LICAM*, *MAP1B*, *BAIAP2L1*, *MAPK3*, *CALD1* and *STK11*. [Figure 1 A]. STRING Protein-protein interaction (PPI) network analysis show the functional association among above proteins and revealed the involvement of these proteins in various pathways such as nervous system development, protein binding, chromosome condensation, and cell cycle regulation [Figure 1 B].

The top enriched KEGG pathways derived from Enrichr database for the above gene set are, Wnt signaling pathway (*CSNK2A1*, *APC*, *CSNK2A2*, *CSNK2B*, *DVLI1*), Adherens junction (*CSNK2A1*, *CSNK2A2*, *CSNK2B*, *MAPK3*), Alzheimer disease (*CSNK2A1*, *APC*, *CSNK2A2*, *CSNK2B*, *DVLI1*, *MAPK3*), PD-L1 expression and PD-1 checkpoint pathway in cancer (*CSNK2A1*, *CSNK2A2*, *CSNK2B*, *MAPK3*) and Pathways of neurodegeneration (*CSNK2A1*, *APC*, *CSNK2A2*, *CSNK2B*, *DVLI1*, *MAPK3*) [Figure 1 C].

The top enriched Synaptic Gene Ontologies derived from the Enrichr database are, Post synapse (*APC*, *CALD1*, *MAP1B*, *STX4*), Regulation of post synapse organization (*DVLI1*, *SHANK2*), Modulation of chemical synaptic transmission (*LICAM*, *MAPK3*), Exocytic insertion of neurotransmitter receptor to postsynaptic membrane (*STX4*) and maintenance of synapse structure (*LICAM*) [Figure 1 D].




Figure 1. Genemania gene network showing the top 20 strongly connected genes with *SHANK2* and *CSNK2A1*. **(A)** SRTING PPI network showing relationship for proteins (nodes) connected (with edges) according to their functional association. **(B)** Bar graph showing the top ten enriched KEGG pathways derived from Enrichr database. **(C)** Bar graph showing top

ten Gene Ontologies (SynGO 2024, a database for Synaptic Gene Ontologies and Annotation) derived from Enrichr database. (D)

Discussion

Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder with complex genetic architecture [8]. In the past few years, the development of genome sequencing technology has advanced the variant discovery. Whole exome sequencing has been used to identify rare and novel genetic variation related to neurodevelopmental disorder [27].

In present study we identified two missense variants one in *SHANK2* (c.401C>G; p.Pro134Arg) another in *CSNK2A1* (c.572G>A; p.Arg191Gln) from the analysis of whole exome sequencing.

SHANK2 (c.401C>G; p.Pro134Arg) is a heterozygous missense variation. It is a novel variation, not observe in 1000 genomes, GnomeAD and ClinVar databases. *In silico* functional impact of this variant is predicted as deleterious.

SHANK2 encodes a protein that is a member of SHANK family of synaptic protein essential for proper synapse formation, development and plasticity [28]. It is located in the postsynaptic density of glutamatergic synapses and encode scaffolding protein [29]. *SHANK* (SH3 and multiple ankyrin repeat domains protein) family genes comprising *SHANK1*, *SHANK2* and *SHANK3* have been linked to a spectrum of neurodevelopmental disorders [30].

CSNK2A1 (c.572G>A, Arg191Gln) is a heterozygous missense variant. It is not observed in 1000 genomes, GnomeAD and ClinVar databases. *In silico* functional impact of this variant is predicted as deleterious. It is a known and previously reported variant [20] and also observed in SFARI gene database.

CSNK2A1 encodes Casein kinase II subunit alpha, a constitutively active and acidophilic serine/threonine protein kinase complex, present in cells in a tetrameric form and composed of two catalytic subunits (α or its isoform α') and two regulatory subunits (β) [31]. It is expressed in eukaryotic organism's all tissues and is essential for normal embryonic development [32]. It phosphorylates large number of substrates and regulates numerous biological processes such as apoptosis, cell proliferation and the DNA damage response [33].

Rare *de novo* *CSNK2A1* variants have been identified in children with ASD, intellectual disability and dysmorphic facial features syndrome [18, 19, 20,].

Gene-network derived from GeneMANIA database show the top 20 strongly connected genes with *SHANK2* and *CSNK2A1* [Figure 1 A]. STRING PPI network analysis show the functional association among these proteins and revealed the involvement in various functions such as proteins binding, synaptogenesis, chromosome condensation and cell cycle regulation [Figure 1 B].

The gene set enrichment analysis using Enrichr tool [26] revealed the major pathways and Gene Ontologies for the above gene set. The top enriched KEGG pathways are, Wnt signaling pathway, Adherens junction, Alzheimer disease, expression and PD-1 checkpoint pathway in cancer and pathways of neurodegeneration [Figure 1 C]. The top enriched Gene Ontologies are Postsynapse organization, Modulation of chemical synaptic transmission, Exocytic insertion of neurotransmitter receptor to postsynaptic membrane and Maintenance of synapse structure [Figure 1 D].

Conclusion

In summary, we identified a novel heterozygous missense *SHANK2* variant along with a known heterozygous missense *CSNK2A1* variant and utilized the existing bioinformatics tools and databases to gain insight into pathways related to autism spectrum disorder. Further, the functional characterization of identified variants in cell and animal models will be needed to understand the pathophysiology of ASD.

References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5), 5th edn Washington, DC: American Psychiatric Association Publishing, 2013.
2. Zeidan, J., Fombonne, E., Scora, J., Ibrahim, A., Durkin, M. S., Saxena, S., Yusuf, A., Shih, A., & Elsabbagh, M. (2022). Global prevalence of autism: A systematic review update. *Autism research: official journal of the International Society for Autism Research*, 15(5), 778–790. <https://doi.org/10.1002/aur.2696>
3. Christensen, D. L., Braun, K. V. N., Baio, J., Bilder, D., Charles, J., Constantino, J. N., Daniels, J., Durkin, M. S., Fitzgerald, R. T., Kurzius-Spencer, M., Lee, L. C., Pettygrove, S., Robinson, C., Schulz, E., Wells, C., Wingate, M. S., Zahorodny, W.,

- & Yeargin-Allsopp, M. (2018). Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012. *Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C.: 2002)*, 65(13), 1–23. <https://doi.org/10.15585/mmwr.ss6513a1>
4. Rogers, S. J., Vismara, L., Wagner, A. L., McCormick, C., Young, G., & Ozonoff, S. (2014). Autism treatment in the first year of life: a pilot study of infant start, a parent-implemented intervention for symptomatic infants. *Journal of autism and developmental disorders*, 44(12), 2981–2995. <https://doi.org/10.1007/s10803-014-2202-y>
 5. Kasari, C., Shire, S., Factor, R., & McCracken, C. (2014). Psychosocial treatments for individuals with autism spectrum disorder across the lifespan: new developments and underlying mechanisms. *Current psychiatry reports*, 16(11), 512. <https://doi.org/10.1007/s11920-014-0512-6>
 6. Grabrucker A. M. (2013). Environmental factors in autism. *Frontiers in psychiatry*, 3, 118. <https://doi.org/10.3389/fpsy.2012.00118>
 7. Goldani, A. A., Downs, S. R., Widjaja, F., Lawton, B., & Hendren, R. L. (2014). Biomarkers in autism. *Frontiers in psychiatry*, 5, 100. <https://doi.org/10.3389/fpsy.2014.00100>
 8. Tordjman, S., Somogyi, E., Coulon, N., Kermarrec, S., Cohen, D., Bronsard, G., Bonnot, O., Weismann-Arcache, C., Botbol, M., Lauth, B., Ginchat, V., Roubertoux, P., Barburoth, M., Kovess, V., Geoffray, M. M., & Xavier, J. (2014). Gene × Environment interactions in autism spectrum disorders: role of epigenetic mechanisms. *Frontiers in psychiatry*, 5, 53. <https://doi.org/10.3389/fpsy.2014.00053>
 9. Devlin, B., & Scherer, S. W. (2012). Genetic architecture in autism spectrum disorder. *Current opinion in genetics & development*, 22(3), 229–237. <https://doi.org/10.1016/j.gde.2012.03.002>
 10. Tick, B., Bolton, P., Happe, F., Rutter, M., and Rijdsdijk, F. (2016). Heritability of autism spectrum disorders: a meta-analysis of twin studies. *J. Child Psychol. Psychiatry* 57, 585–595. <https://doi.org/10.1111/jcpp.12499>.
 11. Hashem, S., Nisar, S., Bhat, A. A., Yadav, S. K., Azeem, M. W., Bagga, P., Fakhro, K., Reddy, R., Frenneaux, M. P., & Haris, M. (2020). Genetics of structural and functional brain changes in autism spectrum disorder. *Translational psychiatry*, 10(1), 229. <https://doi.org/10.1038/s41398-020-00921-3>

12. Durand, C. M., Betancur, C., Boeckers, T. M., Bockmann, J., Chaste, P., Fauchereau, F., Nygren, G., Rastam, M., Gillberg, I. C., Anckarsäter, H., Sponheim, E., Goubran-Botros, H., Delorme, R., Chabane, N., Mouren-Simeoni, M. C., de Mas, P., Bieth, E., Rogé, B., Héron, D., Burglen, L., ... Bourgeron, T. (2007). Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. *Nature genetics*, 39(1), 25–27. <https://doi.org/10.1038/ng1933>
13. Südhof T. C. (2008). Neuroligins and neuexins link synaptic function to cognitive disease. *Nature*, 455(7215), 903–911. <https://doi.org/10.1038/nature07456>
14. Hamdan, F. F., Gauthier, J., Araki, Y., Lin, D. T., Yoshizawa, Y., Higashi, K., Park, A. R., Spiegelman, D., Dobrzyniecka, S., Piton, A., Tomitori, H., Daoud, H., Massicotte, C., Henrion, E., Diallo, O., S2D Group, Shekarabi, M., Marineau, C., Shevell, M., Maranda, B., ... Michaud, J. L. (2011). Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability. *American journal of human genetics*, 88(3), 306–316. <https://doi.org/10.1016/j.ajhg.2011.02.001>
15. Zaslavsky, K., Zhang, W. B., McCready, F. P., Rodrigues, D. C., Deneault, E., Loo, C., Zhao, M., Ross, P. J., El Hajjar, J., Romm, A., Thompson, T., Piekna, A., Wei, W., Wang, Z., Khattak, S., Mufteev, M., Pasceri, P., Scherer, S. W., Salter, M. W., & Ellis, J. (2019). SHANK2 mutations associated with autism spectrum disorder cause hyperconnectivity of human neurons. *Nature neuroscience*, 22(4), 556–564. <https://doi.org/10.1038/s41593-019-0365-8>
16. Bowling, K. M., Thompson, M. L., Amaral, M. D., Finnila, C. R., Hiatt, S. M., Engel, K. L., Cochran, J. N., Brothers, K. B., East, K. M., Gray, D. E., Kelley, W. V., Lamb, N. E., Lose, E. J., Rich, C. A., Simmons, S., Whittle, J. S., Weaver, B. T., Nesmith, A. S., Myers, R. M., Barsh, G. S., ... Cooper, G. M. (2017). Genomic diagnosis for children with intellectual disability and/or developmental delay. *Genome medicine*, 9(1), 43. <https://doi.org/10.1186/s13073-017-0433-1>
17. Abrahams, B. S., Arking, D. E., Campbell, D. B., Mefford, H. C., Morrow, E. M., Weiss, L. A., Menashe, I., Wadkins, T., Banerjee-Basu, S., & Packer, A. (2013). SFARI Gene 2.0: a community-driven knowledgebase for the autism spectrum disorders (ASDs). *Molecular autism*, 4(1), 36. <https://doi.org/10.1186/2040-2392-4-36>

18. Fischbach, G. D., & Lord, C. (2010). The Simons Simplex Collection: a resource for identification of autism genetic risk factors. *Neuron*, *68*(2), 192–195. <https://doi.org/10.1016/j.neuron.2010.10.006>
19. Iossifov, I., O’Roak, B. J., Sanders, S. J., Ronemus, M., Krumm, N., Levy, D., Stessman, H. A., Witherspoon, K. T., Vives, L., Patterson, K. E., Smith, J. D., Paepers, B., Nickerson, D. A., Dea, J., Dong, S., Gonzalez, L. E., Mandell, J. D., Mane, S. M., Murtha, M. T., Sullivan, C. A., ... Wigler, M. (2014). The contribution of de novo coding mutations to autism spectrum disorder. *Nature*, *515*(7526), 216–221. <https://doi.org/10.1038/nature13908>
20. Owen, C. I., Bowden, R., Parker, M. J., Patterson, J., Patterson, J., Price, S., Sarkar, A., Castle, B., Deshpande, C., Splitt, M., Ghali, N., Dean, J., Green, A. J., Crosby, C., Deciphering Developmental Disorders Study, & Tatton-Brown, K. (2018). Extending the phenotype associated with the CSNK2A1-related Okur-Chung syndrome-A clinical study of 11 individuals. *American journal of medical genetics. Part A*, *176*(5), 1108–1114. <https://doi.org/10.1002/ajmg.a.38610>
21. Chakraborty, S., Bhatia, T., Sharma, V., Antony, N., Das, D., Sahu, S., Sharma, S., Shriharsh, V., Brar, J. S., Iyengar, S., Singh, R., Nimgaonkar, V. L., & Deshpande, S. N. (2021). Psychometric properties of a screening tool for autism in the community- The Indian Autism Screening Questionnaire (IASQ). *PloS one*, *16*(4), e0249970. <https://doi.org/10.1371/journal.pone.0249970>
22. Schwarz JM, Cooper DN, Schuelke M, Seelow D. **MutationTaster2: mutation prediction for the deep-sequencing age.** *Nat Methods*. 2014 Apr;11(4):361-2.
23. Warde-Farley, D., Donaldson, S. L., Comes, O., Zuberi, K., Badrawi, R., Chao, P., Franz, M., Grouios, C., Kazi, F., Lopes, C. T., Maitland, A., Mostafavi, S., Montojo, J., Shao, Q., Wright, G., Bader, G. D., & Morris, Q. (2010). The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. *Nucleic acids research*, *38*(Web Server issue), W214–W220. <https://doi.org/10.1093/nar/gkq537>
24. Zuberi, K., Franz, M., Rodriguez, H., Montojo, J., Lopes, C. T., Bader, G. D., & Morris, Q. (2013). GeneMANIA prediction server 2013 update. *Nucleic acids research*, *41*(Web Server issue), W115–W122. <https://doi.org/10.1093/nar/gkt533>
25. Szklarczyk, D., Kirsch, R., Koutrouli, M., Nastou, K., Mehryary, F., Hachilif, R., Gable, A. L., Fang, T., Doncheva, N. T., Pyysalo, S., Bork, P., Jensen, L. J., & von Mering, C. (2023). The STRING database in 2023: protein-protein association

- networks and functional enrichment analyses for any sequenced genome of interest. *Nucleic acids research*, 51(D1), D638–D646. <https://doi.org/10.1093/nar/gkac1000>
26. Kuleshov, M. V., Jones, M. R., Rouillard, A. D., Fernandez, N. F., Duan, Q., Wang, Z., Koplev, S., Jenkins, S. L., Jagodnik, K. M., Lachmann, A., McDermott, M. G., Monteiro, C. D., Gundersen, G. W., & Ma'ayan, A. (2016). Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic acids research*, 44(W1), W90–W97. <https://doi.org/10.1093/nar/gkw377>
 27. O’Roak, B. J., Deriziotis, P., Lee, C., Vives, L., Schwartz, J. J., Girirajan, S., Karakoc, E., Mackenzie, A. P., Ng, S. B., Baker, C., Rieder, M. J., Nickerson, D. A., Bernier, R., Fisher, S. E., Shendure, J., & Eichler, E. E. (2011). Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. *Nature genetics*, 43(6), 585–589. <https://doi.org/10.1038/ng.835>
 28. Boeckers, T. M., Bockmann, J., Kreutz, M. R., & Gundelfinger, E. D. (2002). ProSAP/Shank proteins - a family of higher order organizing molecules of the postsynaptic density with an emerging role in human neurological disease. *Journal of neurochemistry*, 81(5), 903–910. <https://doi.org/10.1046/j.1471-4159.2002.00931.x>
 29. Cooper, G. M., Coe, B. P., Girirajan, S., Rosenfeld, J. A., Vu, T. H., Baker, C., Williams, C., Stalker, H., Hamid, R., Hannig, V., Abdel-Hamid, H., Bader, P., McCracken, E., Niyazov, D., Leppig, K., Thiese, H., Hummel, M., Alexander, N., Gorski, J., Kussmann, J., ... Eichler, E. E. (2011). A copy number variation morbidity map of developmental delay. *Nature genetics*, 43(9), 838–846. <https://doi.org/10.1038/ng.909>
 30. Leblond, C. S., Nava, C., Polge, A., Gauthier, J., Hugué, G., Lumbroso, S., Giuliano, F., Stordeur, C., Depienne, C., Mouzat, K., Pinto, D., Howe, J., Lemièrre, N., Durand, C. M., Guibert, J., Ey, E., Toro, R., Peyre, H., Mathieu, A., Amsellem, F., ... Bourgeron, T. (2014). Meta-analysis of SHANK Mutations in Autism Spectrum Disorders: a gradient of severity in cognitive impairments. *PLoS genetics*, 10(9), e1004580. <https://doi.org/10.1371/journal.pgen.1004580>
 31. Pinna L. A. (2002). Protein kinase CK2: a challenge to canons. *Journal of cell science*, 115(Pt 20), 3873–3878. <https://doi.org/10.1242/jcs.00074>
 32. Lou, D. Y., Dominguez, I., Toselli, P., Landesman-Bollag, E., O'Brien, C., & Seldin, D. C. (2008). The alpha catalytic subunit of protein kinase CK2 is required for mouse

embryonic development. *Molecular and cellular biology*, 28(1), 131–139.

<https://doi.org/10.1128/MCB.01119-07>

33. Roffey, S. E., & Litchfield, D. W. (2021). CK2 Regulation: Perspectives in 2021. *Biomedicines*, 9(10), 1361. <https://doi.org/10.3390/biomedicines9101361>